Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Taavi K. Neklesa"'
Autor:
Taavi K Neklesa, Ronald W Davis
Publikováno v:
PLoS Genetics, Vol 5, Iss 6, p e1000515 (2009)
TORC1 is a central regulator of cell growth in response to amino acid availability, yet little is known about how it is regulated. Here, we performed a reverse genetic screen in yeast for genes necessary to inactivate TORC1. The screen consisted of m
Externí odkaz:
https://doaj.org/article/292fe920a0a24e08a489dc56b8deebfe
Autor:
Andrew P. Crew, Ron Peck, Xin Chen, Deborah A. Gordon, Hanqing Dong, Jennifer Pizzano, John Houston, Jennifer Macaluso, Taavi K. Neklesa, Craig M. Crews, Nicholas Vitale, Ian Taylor, Caterina Ferraro, Lawrence Snyder, Jing Wang, Ryan R. Willard, Marcia Dougan Moore
Publikováno v:
Cancer Research. 81:43-43
Prostate cancer is the second leading cause of cancer death in men in the United States. The androgen receptor (AR) plays critical roles in both early disease and advanced prostate cancer. Current therapeutic approaches targeting the androgen/AR axis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::816bc8632c397c4f312fbaf039fe9f63
https://doi.org/10.1158/1538-7445.am2021-43
https://doi.org/10.1158/1538-7445.am2021-43
Autor:
Andrew P. Crew, Taavi K. Neklesa, Donald P. McDonnell, Craig M. Crews, Shanique B. Alabi, Jemilat Salami, Hanqing Dong, Meizhong Jin, Nick J. Vitale, Jing Wang, Ryan R. Willard
Publikováno v:
Communications Biology, Vol 1, Iss 1, Pp 1-9 (2018)
The androgen receptor is a major driver of prostate cancer and inhibition of its transcriptional activity using competitive antagonists, such as enzalutamide remains a frontline therapy for prostate cancer management. However, the majority of patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51046816fbe40eda42878432d778b9de
https://pubmed.ncbi.nlm.nih.gov/30271980
https://pubmed.ncbi.nlm.nih.gov/30271980
Autor:
Jeffrey L. Gustafson, Taavi K. Neklesa, D. Blake Stagg, Anke G. Roth, John Hines, Thomas B. Sundberg, John D. Norris, Carly S. Cox, Donald P. McDonnell, Hyun Seop Tae, Craig M. Crews, Dennis L. Buckley
Publikováno v:
Angewandte Chemie International Edition. 54:9659-9662
Androgen Receptor (AR)-dependent transcription is a major driver of prostate tumor cell proliferation. Consequently, it is the target of several antitumor chemotherapeutic agents, including the AR antagonist MDV3100/enzalutamide. Recent studies have
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c84b358485da688fee4cdab1a890c0a
https://doi.org/10.1002/anie.201503720
https://doi.org/10.1002/anie.201503720
Autor:
Alicia Morgan, Kevin Coleman, Dominico Vigil, Caterina Ferraro, Andrew P. Crew, Kam W. Siu, Brian D. Hamman, James D. Winkler, Jing Wang, Yevgeniy V. Serebrenik, Craig M. Crews, Yimin Qian, Taavi K. Neklesa, Kanak Raina, Hanqing Dong
Publikováno v:
Journal of medicinal chemistry. 61(2)
Proteolysis targeting chimeras (PROTACs) are bifunctional molecules that recruit an E3 ligase to a target protein to facilitate ubiquitination and subsequent degradation of that protein. While the field of targeted degraders is still relatively young
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e53e69a07899fd55762d8047933dd61
https://pubmed.ncbi.nlm.nih.gov/28692295
https://pubmed.ncbi.nlm.nih.gov/28692295
Publikováno v:
Pharmacologytherapeutics. 174
Targeted protein degradation using the PROTAC technology is emerging as a novel therapeutic method to address diseases driven by the aberrant expression of a disease-causing protein. PROTAC molecules are bifunctional small molecules that simultaneous
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b3c5e93dddea5c01df27bb1081aee56
https://pubmed.ncbi.nlm.nih.gov/28223226
https://pubmed.ncbi.nlm.nih.gov/28223226
Autor:
Taavi K. Neklesa, John J. Flanagan
Publikováno v:
Molecular and Cellular Endocrinology. 493:110452
Nuclear receptors comprise a class of intracellular transcription factors whose major role is to act as sensors of various stimuli and to convert the external signal into a transcriptional output. Nuclear receptors (NRs) achieve this by possessing a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfa6327548bbc161bdf73682513d8277
https://doi.org/10.1016/j.mce.2019.110452
https://doi.org/10.1016/j.mce.2019.110452
Autor:
Caterina Ferraro, Jing Wang, Ryan R. Willard, Taavi K. Neklesa, Jennifer Pizzano, John Houston, Ian Taylor, Gan Wang, Nicholas Vitale, Andrew P. Crew, Deborah A. Gordon, Hanqing Dong, Mark Bookbinder, Jennifer Macaluso, Craig M. Crews, Lawrence Snyder
Publikováno v:
Journal of Clinical Oncology. 37:259-259
259 Background: The Androgen Receptor (AR) remains the principal driver of castration-resistant prostate cancer during the transition from a localized to metastatic disease. Most patients initially respond to inhibitors of the AR pathway, but the res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::56d2b6c51ddc527683400691399255ce
https://doi.org/10.1200/jco.2019.37.7_suppl.259
https://doi.org/10.1200/jco.2019.37.7_suppl.259
Autor:
Alexander P. Kuzin, Devin J. Noblin, Thomas Acton, Craig M. Crews, Liang Tong, G. Kornhaber, Gaetano T. Montelione, Scott Lew, Jayaraman Seetharaman, Taavi K. Neklesa, Rong Xiao
Publikováno v:
ACS Chemical Biology. 8:2293-2300
Small molecule control of intracellular protein levels allows temporal and dose-dependent regulation of protein function. Recently, we developed a method to degrade proteins fused to a mutant dehalogenase (HaloTag2) using small molecule hydrophobic t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a0d0faaf690fbb988c268e92152d156
https://doi.org/10.1021/cb400569k
https://doi.org/10.1021/cb400569k
Autor:
Craig M. Crews, Thomas B. Sundberg, Taavi K. Neklesa, Devin J. Noblin, Kanak Raina, Hyun Seop Tae, Anke G. Roth, Jeffrey L. Gustafson
Publikováno v:
ChemBioChem. 13:538-541
New HyTs are a knockout: we previously reported that labeling HaloTag proteins with low molecular weight hydrophobic tags (HyTs) leads to targeted degradation of HaloTag fusion proteins. In this report, we employed a chemical approach to extend this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75455df3cf517cbee326e8900d6594a6
https://doi.org/10.1002/cbic.201100793
https://doi.org/10.1002/cbic.201100793